From maturity to value-added innovation: Lessons from the pharmaceutical and agro-biotechnology industries

Trends in Biotechnology

Volumn 29, Issue 3, 2011, Pages 105-109

  Mittra, James ^a   Tait, Joyce ^a   Wield, David ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY INDUSTRY; INNOVATION SYSTEM; LIFE-SCIENCES; NEW HIGH; RAPID DEVELOPMENT; REGULATORY SYSTEMS; RESEARCH AND DEVELOPMENT; SMALL MOLECULES;

BIOTECHNOLOGY; PIPELINES;

INDUSTRY;

AGRONOMY; BIOMEDICINE; BIOTECHNOLOGY; DRUG INDUSTRY; DRUG MARKETING; MEDICAL RESEARCH; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SHORT SURVEY;

BIOTECHNOLOGY; DRUG INDUSTRY; GOVERNMENT REGULATION; RESEARCH;

EID: 79951671970     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2010.11.004     Document Type: Short Survey

References (32)

1. Chiesa V., Toletti G. Network of collaborations for innovation: the case of biotechnology. Technol. Anal. Strat. Manag. 2004, 16:73-96.
2. Mittra J. Life science innovation and the restructuring of the pharmaceutical industry: merger, acquisition and strategic alliance behaviour large firms. Technol. Anal. Strat. Manag. 2007, 19:279-301.
3. Mittra J., Williams R. Editorial: evolution of the life science industries. Technol. Anal. Strat. Manag. 2007, 19:251-255.
4. Tait J. Systemic interactions in life science innovation. Technol. Anal. Strat. Manag. 2007, 19:257-277.
5. Tait, J. et al. eds (2001) Policy Influences on Technology for Agriculture: Chemicals, Biotechnology and Seeds Final Report, Policy Influences on Technology for Agriculture (PITA), Report to European Commission Targeted Socio-Economic Research Programme (TSER), Project no. SOE1/CT97/1068. URL: ftp://ftp.cordis.europa.eu/pub/citizens/docs/pita_20966.pdf.
6. Chataway J., et al. The governance of agro- and pharmaceutical biotechnology innovation: public policy and industrial strategy. Technol. Anal. Strat. Manag. 2006, 18:169-185.
7. Niiler E. Demise of the life science company begins. Nat. Biotechnol. 2000, 18:14.
8. Walsh V., Lodorfos G. Technological and organisational innovation in chemicals and related products. Technol. Anal. Strat. Manag. 2002, 14:273-298.
9. Chataway J., et al. Understanding company R&D strategies in agro-biotechnology: trajectories and blind spots. Res. Policy 2004, 33:1041-1057.
10. Tait J., Chataway J. The governance of corporations, technological change, and risk: examining industrial perspectives on the development of genetically modified crops. Environ. Plan. C: Govt. Policy 2007, 25:21-37.
11. Granstrand O.P.P., Pavitt K. Multi-technology corporations: why they have " distributed" rather than " distinctive core" competences. California Manag. Rev. 1997, 39:8-25.
12. Dosi G., et al. Technol. Change and Econ. Theory 1988, Pinter.
13. Teece D.J., Pisano G., Schuen A. Dynamic capabilities and strategic management. Strategic Manag. J. 1997, 18:509-530.
14. Mittra J. Impact of the life sciences on organisation and management of R&D in large pharmaceutical firms. Int. J. Biotechnol. 2008, 10:416-440.
15. Nightingale P. Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D. Ind. Corporate Change 2000, 9:315-359.
16. Drews J. Drug discovery: a historical perspective. Science 2000, 287:1960-1964.
17. Cambrosio A., Keating P., Mogoutov A. Mapping collaborative work and innovation in biomedicine. Soc. Stud. Sci. 2004, 34:325-364.
18. Coombs R., Metcalfe S. Innovation in pharmaceuticals: perspectives on the co-ordination, combination and creation of capabilities. Technol. Anal. and Strat. Manag. 2002, 14:261-271.
19. Drews J., Ryser S. The innovation deficit in the pharmaceutical industry. Drug Inf. J. 1996, 30:97-108.
20. Horrobin D.F. Realism in drug discovery - could Cassandra be right?. Nat. Biotechnol. 2001, 19:1099-1100.
21. Horig, H. and Pullman, W. (2004) From bench to clinic and back: perspective on the 1st IQPC Translational Research Conference. J. Trans. Med. 2, 44.
22. Pardridge W.M. Translational science: what is it and why is it so important?. Drug Discov. Today 2003, 18:813-815.
23. Dimasi J.A., Grabowski H.G. The cost of biopharmaceutical R&D: is biotech different?. Managerial and Decis. Econ. 2007, 28:469-479.
24. Tait J., Mittra J. Industry challenges. Chem. Ind. 2004, 23:24.
25. Dorey E. GlaxoSmithKline presents a biotech façade. Nat. Biotechnol. 2001, 19:294-295.
26. Wield D., et al. Issues in the political economy of agricultural biotechnology. J. Agrarian Change 2010, 10:342-366.
27. Milne C.P. Fixing the paradigm for biopharmaceuticals R&D: where to start?. Inter. J. Biotechnol. 2008, 10:404-415.
28. Tait, J. et al. (2008) Health Biotechnology to 2030. Report to OECD International Futures Project, " The Bio-Economy to 2030: Designing a Policy Agenda", OECD, Paris. Available at: http://www.oecd.org/dataoecd/12/10/40922867.pdf.
29. Tait J., Williams R. Policy approaches to research and development: foresight, framework and competitiveness. Sci. Pub. Policy 1999, 26:101-112.
30. Tait J., et al. Governance, policy and industry strategies: pharmaceuticals and agro-biotechnology. Knowledge Accumulation and Industry Evolution 2006, 378-401. Cambridge University Press. M. Mazzucato, G. Dosi (Eds.).
31. Schellekens H., Moors E. Clinical comparability and European biosimilar regulations. Nat. Biotechnol. 2010, 28:28-31.
32. Bravery C.A. Regulating interface science healthcare products: myths and uncertainties. J. R. Soc. 2010, 7:789-795.